High prevalence of Parkinsonian disorders associated to manganese exposure in the vicinities of ferroalloy industries.

OBJECTIVE To assess the prevalence of Parkinsonian disturbances in relationship to environmental exposure to manganese due to ferroalloy industries in the province of Brescia, Northern Italy. METHODS Manganese concentrations were measured in settled dust collected in each of the 206 municipalities. Parkinsonian patients were identified using two sources: (1) clinical registers from local hospitals, specialized neurologists, and exemption from prescription payment; (2) L-Dopa prescriptions. Standardized prevalence rates and raw and full Bayesian-smoothed standardized morbidity ratios (SMRs) were calculated for the entire province and for each municipality. RESULTS Manganese concentrations in settled dust were significantly higher in the surroundings and downwind from the industrial plants. A total number of 2,677 Parkinsonian cases were identified among 903,997 residents (crude prevalence, 296/100,000; 95% CI: 284.80-307.20; standardized prevalence, 407/100,000; 95% CI: 393.87-420.12). Significantly higher SMRs (Kruskal-Wallis chi(2) 1 df = 17.55, P < 0.001) were observed in 37 municipalities in the vicinities of ferromanganese plants (324 cases among 77,708 residents; standardized prevalence 492/100,000; 95% CI: 442.80-541.20), compared to the other 169 municipalities of the province (2,353 cases among 826,289 residents, standardized prevalence 321/100,000; 95% CI 308.80-333.20). Row and Bayesian SMRs were associated with the concentrations of manganese in settled dust. CONCLUSION Study results suggest that environmental exposure to manganese is associated with an increased prevalence of Parkinsonian disturbances. Since the highest prevalence rates were observed in a closed community of the pre-Alps where the industries are located, further research should address a possible interactive role of genetic factors.

[1]  Michael Jerrett,et al.  A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. , 2007, Environmental research.

[2]  K. Leenders,et al.  Hydrocarbon exposure and Parkinson’s disease , 2000, Neurology.

[3]  K. Teschke,et al.  The prevalence of Parkinson's disease in British Columbia, Canada, estimated by using drug tracer methodology. , 2003, Parkinsonism & related disorders.

[4]  F. Larribe,et al.  Bioindicator and exposure data for a population based study of manganese. , 1999, Neurotoxicology.

[5]  M. Egyed,et al.  Risk assessment for combustion products of the gasoline additive MMT in Canada , 1996 .

[6]  J. Texcalac-Sangrador,et al.  Exposure to manganese: health effects on the general population, a pilot study in central Mexico. , 2001, Environmental research.

[7]  B. Sonawane,et al.  Neurodegenerative Diseases: An Overview of Environmental Risk Factors , 2005, Environmental health perspectives.

[8]  P. Landrigan,et al.  The Declaration of Brescia on prevention of the neurotoxicity of metals June 18, 2006. , 2006, American journal of industrial medicine.

[9]  Freya Kamel,et al.  Association of Pesticide Exposure with Neurologic Dysfunction and Disease , 2004, Environmental health perspectives.

[10]  K. Bötzel,et al.  Prevalence and incidence of Parkinson's disease in Europe , 2005, European Neuropsychopharmacology.

[11]  D. Jennings,et al.  Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders , 2005, Neurology.

[12]  G. Román,et al.  Worldwide occurrence of Parkinson's disease: an updated review. , 1993, Neuroepidemiology.

[13]  A. Vyskočil,et al.  Environmental contamination and human exposure to manganese – contribution of methylcyclopentadienyl manganese tricarbonyl in unleaded gasoline , 1999, International archives of occupational and environmental health.

[14]  W. Koller,et al.  The diagnosis of manganese-induced parkinsonism. , 2006, Neurotoxicology.

[15]  G. Meco,et al.  Estimate of parkinsonism prevalence through drug prescription histories in the Province of Rome, Italy , 1995, Acta neurologica Scandinavica.

[16]  Daniel J Schaid,et al.  Risk tables for parkinsonism and Parkinson's disease. , 2002, Journal of clinical epidemiology.

[17]  Bernard Weiss,et al.  Economic implications of manganese neurotoxicity. , 2006, Neurotoxicology.

[18]  Zhenxin Zhang,et al.  Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai , 2005, The Lancet.

[19]  P. Apostoli,et al.  Are current biomarkers suitable for the assessment of manganese exposure in individual workers? , 2000, American journal of industrial medicine.

[20]  P Apostoli,et al.  Neurobehavioral effects of manganese in workers from a ferroalloy plant after temporary cessation of exposure. , 1995, Scandinavian journal of work, environment & health.

[21]  H. Kay Environmental Health Criteria , 1980 .

[22]  T. Videen,et al.  [18F]FDOPA PET and clinical features in parkinsonism due to manganism , 2005, Movement disorders : official journal of the Movement Disorder Society.

[23]  M. Allam,et al.  Parkinson's disease risk factors: genetic, environmental, or both? , 2005, Neurological research.

[24]  P Apostoli,et al.  Long-term exposure to "low levels" of manganese oxides and neurofunctional changes in ferroalloy workers. , 1999, Neurotoxicology.

[25]  Andrew Thomas,et al.  WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility , 2000, Stat. Comput..

[26]  U. Siebert,et al.  Cost of Parkinson's disease in Europe , 2005, European journal of neurology.

[27]  A. Chiò,et al.  Prevalence of Parkinson's disease in northwestern italy: Comparison of tracer methodology and clinical ascertainment of cases , 1998, Movement disorders : official journal of the Movement Disorder Society.

[28]  Samuel M. Goldman,et al.  EPIDEMIOLOGY OF PARKINSON'S DISEASE , 1996, Neurologic Clinics.

[29]  S. Sacco,et al.  Prevalence of Parkinson's disease in the L'Aquila district, central Italy , 2005, Acta neurologica Scandinavica.

[30]  J. Mink,et al.  Welding-related parkinsonism , 2001, Neurology.

[31]  Joshua M. Pearce,et al.  Neurodegeneration with Brain Iron Accumulation: A Cautionary Tale , 2006, European Neurology.

[32]  Christopher J. Martin Manganese neurotoxicity: connecting the dots along the continuum of dysfunction. , 2006, Neurotoxicology.

[33]  M. Farrer Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.

[34]  J. Roth,et al.  Iron interactions and other biological reactions mediating the physiological and toxic actions of manganese. , 2003, Biochemical pharmacology.

[35]  Carlos Santos-Burgoa,et al.  Motor alterations associated with exposure to manganese in the environment in Mexico. , 2006, The Science of the total environment.

[36]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[37]  O. Axelson,et al.  Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. , 1996, Journal of clinical epidemiology.